| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2017-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00933052a9b46b7fba983aff3aefbe55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e28e6558a91bac1f5297ce9038af6544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d633249675425480fcdba755d57f6793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c42536c13d2af548ac03635d7195c3f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f45f1dcef4009b5d8092ea0b7f0282c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c8305b5554612aca288f1e576225e0b |
| publicationDate |
2017-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017134600-A1 |
| titleOfInvention |
New use of a combination of sacubitril and valsartan |
| abstract |
: The present invention relates to methods and pharmaceutical compositions for treating heart failure in a pediatric human patient comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril and valsartan in a pharmaceutically acceptable form and in a 1:1 molar ratio. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021525791-A |
| priorityDate |
2016-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |